For: |
Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i46/13124.htm |
Number | Citing Articles |
1 |
Dan Wang, Qianqian Guo, Yuan Yuan, Yuehua Gong. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC Microbiology 2019; 19(1) doi: 10.1186/s12866-019-1517-4
|
2 |
Hideki Mori, Hidekazu Suzuki. Update on quinolone-containing rescue therapies for <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2020; 26(15): 1733-1744 doi: 10.3748/wjg.v26.i15.1733
|
3 |
Muhammet Yener Akpinar, Evrim Kahramanoglu Aksoy, Ferdane Sapmaz, Zeynep Goktas, Metin Uzman, Yasar Nazligul. Comparison of moxifloxacin-based therapies and standard bismuth-based quadruple therapy for first-line treatment of Helicobacter pylori infection. Archives of Medical Science – Civilization Diseases 2018; 3(1): 81 doi: 10.5114/amscd.2018.78766
|
4 |
Sumaira Khadim, Iyad Naeem Muhammad, Tanveer Alam, Shahnaz Usman, Hina Rehman, Sajjad Haider. Predictors of Successful First-Line Helicobacter pylori Eradication with Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors. Antibiotics 2024; 13(3): 211 doi: 10.3390/antibiotics13030211
|
5 |
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opinion on Pharmacotherapy 2022; 23(1): 63 doi: 10.1080/14656566.2021.1959914
|
6 |
Alicia C. Marin, Olga P. Nyssen, Adrian G. McNicholl, Javier P. Gisbert. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017; 77(7): 765 doi: 10.1007/s40265-017-0730-4
|
7 |
Brian White, Maria Winte, Joshua DeSipio, Sangita Phadtare. Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients. Microorganisms 2022; 10(2): 322 doi: 10.3390/microorganisms10020322
|
8 |
Anthony O'Connor, Wolfgang Fischbach, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2016. Helicobacter 2016; 21(S1): 55 doi: 10.1111/hel.12342
|
9 |
Andrzej Czyrski, Agnieszka Sokół, Edyta Szałek. HPLC method for determination of moxifloxacin in plasma and its application in pharmacokinetic analysis. Journal of Liquid Chromatography & Related Technologies 2017; 40(1): 8 doi: 10.1080/10826076.2017.1280680
|
10 |
Darsh Gautam, Poonam Talwan, Sahil Dhiman, Rahul Gill, Aparna Thakur, Simran Dhiman, Deexa Sharma, Akhil Kumar, Saksham Sharma. Amoxicillin-loaded Nanotechnological Carriers for the Effective
Treatment of Helicobacter pylori Infection. Micro and Nanosystems 2023; 15(4): 245 doi: 10.2174/0118764029259927231127094657
|
11 |
Yuehua Gong, Yuan Yuan. Resistance mechanisms ofHelicobacter pyloriand its dual target precise therapy. Critical Reviews in Microbiology 2018; 44(3): 371 doi: 10.1080/1040841X.2017.1418285
|
12 |
Jing Yu, Yiming Lv, Peng Yang, Yizhou Jiang, Xiangrong Qin, Xiaoyong Wang. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-03002-z
|
13 |
Emily C. Tucker, Matthew B. Roberts, David L. Gordon. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2017; 39: 229 doi: 10.1016/bs.seda.2017.07.005
|